Skip to main content

Advertisement

SpringerLink
Log in

Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Abbreviations

HCT:

hematopoietic cell transplantation

JAK2:

Janus kinase 2

JAK-STAT:

Janus kinase-signal transducer and activator of transcription

PD-L1/2:

programmed cell-death ligand ½

PMBL:

primary mediastinal B-cell lymphoma

References

  1. Gaulard P, Harris NL, Pileri SA. (2017) Primary mediastinal (thymic) large B-cell lymphoma. In Swerdlow SH, Camp E, Harris NL, et al WHO classification of tumours of haematopoeitic and lymphoid tissues Revised 4th ed International Agency for Research on Cancer:314–316

  2. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, de Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RC, Li S, Salles G, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102(12):3871–3879. https://doi.org/10.1182/blood-2003-06-1841

    Article  CAS  PubMed  Google Scholar 

  3. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17):3268–3277. https://doi.org/10.1182/blood-2010-05-282780

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Steidl C, Gascoyne RD (2011) The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 118(10):2659–2669. https://doi.org/10.1182/blood-2011-05-326538

    Article  CAS  PubMed  Google Scholar 

  5. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408–1416. https://doi.org/10.1056/NEJMoa1214561

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group., Eastern Cooperative Oncology Group., European Mantle Cell Lymphoma Consortium., Italian Lymphoma Foundation., European Organisation for Research., Treatment of Cancer/Dutch Hemato-Oncology Group., Grupo Español de Médula Ósea., German High-Grade Lymphoma Study Group., German Hodgkin's Study Group., Japanese Lymphorra Study Group., Lymphoma Study Association., NCIC Clinical Trials Group., Nordic Lymphoma Study Group., Southwest Oncology Group., United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068. https://doi.org/10.1200/JCO.2013.54.8800

    Article  PubMed Central  PubMed  Google Scholar 

  7. Zinzani PL, Pellegrini C, Chiappella A, di Rocco A, Salvi F, Cabras MG, Argnani L, Stefoni V (2017) Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood 129(16):2328–2330. https://doi.org/10.1182/blood-2017-01-764258

    Article  CAS  PubMed  Google Scholar 

  8. Kim JS, Kang HJ, Dong S et al (2016) The efficacy of JAK2 inhibitor in heavily pretreated classical Hodgkin lymphoma: a prospective pilot study of ruxolitinib in relapsed or refractory classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 128:1820

    Google Scholar 

  9. Zinzani PL, Ribrag V, Moskiwitz CH et al (2017) Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 130(3):267–270. https://doi.org/10.1182/blood-2016-12-758383

    Article  CAS  PubMed  Google Scholar 

  10. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062–2068. https://doi.org/10.1038/leu.2015.212

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Availability of data and material

All data generated or analyzed are in the current report.

Author information

Authors and Affiliations

  1. Department of Hematology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands

    Marcel Nijland, Tom van Meerten & Gerwin Huls

  2. Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands

    Annika Seitz, Lydia Visser, Anke van den Berg & Arjan Diepstra

  3. Department of Pathology, Pathology Friesland, Leeuwarden, the Netherlands

    Robby Kibbelaar

Authors
  1. Marcel Nijland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tom van Meerten
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Annika Seitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gerwin Huls
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robby Kibbelaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lydia Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anke van den Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Arjan Diepstra
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MN designed the paper. MN, TM, and GH treated the patient. AD and RK provided pathological review. AS, LV, and AB performed FISH analysis. All authors contributed in writing the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Marcel Nijland.

Ethics declarations

Ethics approval and consent to participate

The patient provided informed consent for all her sequential therapies.

Consent for publication

Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Conflict of interests

The authors declare that they have no conflict interests.

Electronic supplementary material

ESM 1

(DOCX 23 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nijland, M., van Meerten, T., Seitz, A. et al. Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma. Ann Hematol 97, 905–907 (2018). https://doi.org/10.1007/s00277-018-3233-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3233-9

Search

Navigation